Raymond James initiates Kymera Therapeutics stock coverage with outperform rating

Raymond James has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with an "Outperform" rating and set a price target of $140.00, presenting a potential upside of around 28%. The stock is currently trading at $109.34, which suggests the company's current valuation might be slightly overvalued according to the firm's analysis.

Kymera Therapeutics is developing small molecule targeted protein degraders to treat autoimmune and inflammatory conditions, with their lead candidate, KT-621, being an oral STAT6 degrader. The drug has potential applications in Type 2 inflammatory diseases. Raymond James is focusing on the biotechnology company's risk/reward profile ahead of the top-line results from the Phase 2b BROADEN2 trial for KT-621, which is expected by the end of 2026.

Wall Street is generally bullish on Kymera Therapeutics, with a consensus rating of 1.35, classified as "strong buy" territory, and a range of analyst price targets from $111 to $180.